Overview

Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer

Status:
Not yet recruiting

Trial end date:
2026-04-30

Target enrollment:

Participant gender:

Summary

This is a multicenter, Phase 1b-2 study of elacestrant in combination with onapristone in patients with advanced/metastatic ER+/PgR+/HER2- breast cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Context Therapeutics Inc.

Treatments:

Onapristone